|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PAQR4 |
Gene summary for PAQR4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PAQR4 | Gene ID | 124222 |
| Gene name | progestin and adipoQ receptor family member 4 | |
| Gene Alias | PAQR4 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N4S7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 124222 | PAQR4 | LZE7T | Human | Esophagus | ESCC | 6.42e-03 | 1.43e-01 | 0.0667 |
| 124222 | PAQR4 | LZE22T | Human | Esophagus | ESCC | 2.20e-03 | 3.20e-01 | 0.068 |
| 124222 | PAQR4 | LZE24T | Human | Esophagus | ESCC | 9.65e-07 | 3.39e-01 | 0.0596 |
| 124222 | PAQR4 | P1T-E | Human | Esophagus | ESCC | 1.38e-02 | 2.26e-01 | 0.0875 |
| 124222 | PAQR4 | P2T-E | Human | Esophagus | ESCC | 6.64e-48 | 1.10e+00 | 0.1177 |
| 124222 | PAQR4 | P4T-E | Human | Esophagus | ESCC | 2.67e-08 | 2.70e-01 | 0.1323 |
| 124222 | PAQR4 | P5T-E | Human | Esophagus | ESCC | 2.55e-15 | 3.52e-01 | 0.1327 |
| 124222 | PAQR4 | P8T-E | Human | Esophagus | ESCC | 1.35e-14 | 4.61e-01 | 0.0889 |
| 124222 | PAQR4 | P10T-E | Human | Esophagus | ESCC | 1.20e-02 | 8.97e-02 | 0.116 |
| 124222 | PAQR4 | P11T-E | Human | Esophagus | ESCC | 4.40e-08 | 3.87e-01 | 0.1426 |
| 124222 | PAQR4 | P12T-E | Human | Esophagus | ESCC | 3.41e-13 | 3.29e-01 | 0.1122 |
| 124222 | PAQR4 | P15T-E | Human | Esophagus | ESCC | 7.12e-14 | 3.85e-01 | 0.1149 |
| 124222 | PAQR4 | P16T-E | Human | Esophagus | ESCC | 1.21e-11 | 2.41e-01 | 0.1153 |
| 124222 | PAQR4 | P17T-E | Human | Esophagus | ESCC | 6.57e-13 | 5.57e-01 | 0.1278 |
| 124222 | PAQR4 | P19T-E | Human | Esophagus | ESCC | 2.67e-06 | 5.82e-01 | 0.1662 |
| 124222 | PAQR4 | P20T-E | Human | Esophagus | ESCC | 1.30e-13 | 2.87e-01 | 0.1124 |
| 124222 | PAQR4 | P21T-E | Human | Esophagus | ESCC | 6.44e-13 | 3.17e-01 | 0.1617 |
| 124222 | PAQR4 | P22T-E | Human | Esophagus | ESCC | 1.90e-05 | 1.94e-01 | 0.1236 |
| 124222 | PAQR4 | P23T-E | Human | Esophagus | ESCC | 9.80e-03 | 1.33e-01 | 0.108 |
| 124222 | PAQR4 | P24T-E | Human | Esophagus | ESCC | 9.66e-08 | 2.08e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PAQR4 | SNV | Missense_Mutation | novel | c.716C>T | p.Ser239Phe | p.S239F | Q8N4S7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PAQR4 | SNV | Missense_Mutation | novel | c.383C>T | p.Thr128Ile | p.T128I | Q8N4S7 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PAQR4 | SNV | Missense_Mutation | c.131A>G | p.Tyr44Cys | p.Y44C | Q8N4S7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PAQR4 | SNV | Missense_Mutation | c.635N>C | p.Leu212Pro | p.L212P | Q8N4S7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PAQR4 | SNV | Missense_Mutation | rs868703853 | c.479C>T | p.Ala160Val | p.A160V | Q8N4S7 | protein_coding | tolerated(0.19) | benign(0.021) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| PAQR4 | SNV | Missense_Mutation | rs369198276 | c.328G>A | p.Ala110Thr | p.A110T | Q8N4S7 | protein_coding | tolerated(0.46) | benign(0) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PAQR4 | SNV | Missense_Mutation | rs201549871 | c.437N>A | p.Arg146His | p.R146H | Q8N4S7 | protein_coding | deleterious(0.04) | probably_damaging(0.96) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PAQR4 | SNV | Missense_Mutation | novel | c.262G>A | p.Ala88Thr | p.A88T | Q8N4S7 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| PAQR4 | SNV | Missense_Mutation | rs369198276 | c.328N>A | p.Ala110Thr | p.A110T | Q8N4S7 | protein_coding | tolerated(0.46) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PAQR4 | SNV | Missense_Mutation | rs868732145 | c.638N>T | p.Ala213Val | p.A213V | Q8N4S7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |